the aid library

LIST OPTIONS

Filter

9116

Guideline on when to start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

Elaine Abrams, Tsitsi Apollo, Janet Bhila et al. World Health Organization WHO (2015) C_WHO

The new WHO guidelines recommend that people living with HIV be started on antiretrovirals (ARVs) as soon as possible after being diagnosed. Currently, many people living with the virus globally must wait until their CD4 counts fall to 500 to start treatment. According to the WHO, the move to early ... more

Download (273)

View PDF (380)

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti... more

Download (159)

View PDF (152)

South Africa - Country Cooperation Strategy 2023 - 2027

World Health Organization WHO (2025) C_WHO

The South African WHO Country Cooperation Strategy (CCS) 2023–2027 focuses on four key strategic priorities based on the country’s health needs and disease epidemiology, while also considering the need for building resilient health systems for UHC and health security in the post pandemic period.... more

Download (663)

View PDF (1711)

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec... more

Download (440)

View PDF (662)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (570)

View PDF (852)

India: Guidelines for the Public Private Partnership Model of ART centres

National AIDS Control Organisation (NACO), Government of India (2017) C1

Download (306)

View PDF (433)

WHO technical consultation on oxygen access scale-up for COVID-19

World Health Organization WHO (2021) C_WHO

Download (602)

View PDF (1213)

Generic risk assessment model for insecticide-treated nets, 2nd ed.

World Health Organization (WHO) (2018) C_WHO

Long-lasting insecticidal nets (LNs) constitute a core vector control intervention against malaria. A number of new LN products are under development and will require assessment of risks to humans. This document provides an updated generic model that can be used for the risk assessment of exposure t... more

Download (255)

View PDF (498)

Methamphetamine continues to dominate synthetic drug markets

United Nations Office on Drugs and Crime; Global smart (2018) C2

Volume 20, September Global smart update

Download (237)

View PDF (291)

Treat as One. Bridging the gap between mental and physical healthcare in general hospitals

National Confidential Enquiry into Patient Outcome and Death (2017) C1

This NCEPOD report highlights the quality of mental health and physical health care for patients aged 18 years or older with a significant mental disorder who are admitted to a general hospital. The report takes a critical look at areas where the care of patients might have been improved. Remediable... more

External Link

Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot

Gajda M., E. Urban (2019) CC

Stenotrophomonas maltophiliais a nonfermenting Gram-negative rod that is ubiquitous in nature (predominantly occurring in aquatic environments and on plants). Biochemically, it iscatalase positive and oxidase negative, and it produces acid frommaltose (hence the name“maltophilia”). Due to it... more

Download (431)

View PDF (559)

The Global Status Report on Preventing Violence Against Children 2020

UNICEF WHO (2020) C_WHO

As this report shows, reports of child abuse and of children witnessing violence between their parents and caregivers have increased. Ending violence against children is increasingly within our reach. D

Download (823)

View PDF (1954)

Adolescent HIV Care and Treatment: A Training Curriculum for Health Workers . Module 14 Trainer Manual

ICAP; CDC; University Teaching Hospital, et al. (2011)

Download (326)

View PDF (433)

The impact of Covid-19 on HIV, TB and Malaria Services and Systems for Health: a Snapshot from 502 health facilities across Africa and Asia

The Global Fund (2021) CC

In 2020, the COVID-19 pandemic impacted the world beyond imagination. To date, it has infected more than 135 million people, killed over 2.9 million people, and is projected to plunge up to 115 million people into extreme poverty.1 As countries have gone into lockdown, gender-based violence has incr... more

Download (259)

View PDF (328)

Global competency and outcomes framework for universal health coverage

World Health Organization WHO (2022) C_WHO

Download (361)

View PDF (363)

WHO recommendations on outpatient settings for induction of labour

World Health Organization WHO (2022) C_WHO

The primary audience for these recommendations includes health professionals who are responsible for developing national and local health-care guidelines and protocols and health workers involved in the provision of care to women and their newborns during pregnancy, labour and childbirth; this inclu... more

Download (1339)

View PDF (1640)

World Health Organization Surgical Safety Checklist

Woodman, N.; and I. Walker World Health Organization WHO (2016) C_WHO

Patient Safety tutorial 325

Download (427)

View PDF (586)

Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys

Stevens, Gretchen; Bennett, James et al. (2015) CC

Vitamin A deficiency is a risk factor for blindness and for mortality from measles and diarrhoea in children aged 6–59 months. We aimed to estimate trends in the prevalence of vitamin A defi ciency between 1991 and 2013 and its mortality burden in low-income and middle-income countries.

Download (322)

View PDF (369)

Табак губит сердце. Выбирайте здоровье, а не табак

World Health Organization World Health Organization (2018) C_WHO

Ежегодно табак убивает более 7 миллионов человек (1), то есть ежедневно в результате употребления табака или воздействия вторичного табачного дыма (ВТД) умирает бол�... more

External Link

Closing the mental health treatment gap in South Africa: a review of costs and cost-effectiveness

Jack, H.; R.G. Wagner, I. Petersen, et al. (2014) CC